Portal de Periódicos da CAPES

Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants

2019; American Society for Microbiology; Volume: 63; Issue: 5 Linguagem: Inglês

10.1128/aac.00014-19

1098-6596

Robert A. Smith, Dana N. Raugi, Vincent H. Wu, Christopher G. Zavala, Jennifer Song, Khardiata Diallo, Moussa Seydi, Geoffrey S. Gottlieb, Fatima Sall, Diallo Mouhamadou Baïla, Khadim Faye, Samba Cisse, Marie Pierre Sy, Binetou Diaw, Ousseynou Ndiaye, Babacar Faye, Ndeye Astou Diop, Amadou Bale Diop, Marianne Fadam Diome, Jean Jacques Malomar, ElHadji Ibrahima Sall, Ousseynou Cisse, Ibrahima Tito Tamba, Dominique Faye, Jean Philippe Diatta, Raphael Bakhoum, Sambou Jacques Francois, Gomis Juliette, Therese Dieye, Stephen E. Hawes, Noelle A. Benzekri, John Lin, Robbie Nixon, Pallas Burhen, Ming Chang, Robert W. Coombs, James I. Mullins, Papa Salif Sow, Nancy B. Kiviat,

HIV/AIDS Research and Interventions

We compared the activity of the integrase inhibitor bictegravir against HIV-1 and HIV-2 using a culture-based, single-cycle assay. Values of 50% effective concentrations ranged from 1.2 to 2.5 nM for 9 HIV-1 isolates and 1.4 to 5.6 nM for 15 HIV-2 isolates. HIV-2 integrase mutants G140S/Q148R and G140S/Q148H were 34- and 110-fold resistant to bictegravir, respectively; other resistance-associated mutations conferred ≤5-fold changes in bictegravir susceptibility. Our findings indicate that bictegravir-based antiretroviral therapy should be evaluated in HIV-2-infected individuals.